<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242359</url>
  </required_header>
  <id_info>
    <org_study_id>2085</org_study_id>
    <nct_id>NCT00242359</nct_id>
  </id_info>
  <brief_title>A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma</brief_title>
  <official_title>A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernstein Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bernstein Clinical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Management of animal induced occupational asthma is mainly avoidance, but this is not&#xD;
      feasible for many occupations. Treatment with avoidance and conventional treatment is also&#xD;
      not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and&#xD;
      may be effective at reducing symptoms and disease progression in the animal handlers&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    could not find subject population&#xD;
  </why_stopped>
  <start_date type="Actual">November 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Allergy Induced Asthma</condition>
  <arm_group>
    <arm_group_label>omalizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open-label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omalizumab</intervention_name>
    <arm_group_label>omalizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ages 18-65&#xD;
&#xD;
          2. occupation that involves close contact with animals&#xD;
&#xD;
          3. stable dose of ICS for 30 days&#xD;
&#xD;
          4. Skin test positive to one or more animals&#xD;
&#xD;
          5. evidence of asthma on spirometry&#xD;
&#xD;
          6. demonstrate PEFR variability-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. on allergen immunotherapy&#xD;
&#xD;
          2. on prohibited medications&#xD;
&#xD;
          3. unstable asthma&#xD;
&#xD;
          4. recent URI&#xD;
&#xD;
          5. known hypersensitivity to omalizumab-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 17, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2005</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bernstein Clinical Research Center</investigator_affiliation>
    <investigator_full_name>Jonathan A. Bernstein, MD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

